<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="letter"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Pulm Circ</journal-id><journal-id journal-id-type="iso-abbrev">Pulm Circ</journal-id><journal-id journal-id-type="publisher-id">PUL</journal-id><journal-id journal-id-type="hwp">sppul</journal-id><journal-title-group><journal-title>Pulmonary Circulation</journal-title></journal-title-group><issn pub-type="ppub">2045-8932</issn><issn pub-type="epub">2045-8940</issn><publisher><publisher-name>SAGE Publications</publisher-name><publisher-loc>Sage UK: London, England</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29565224</article-id><article-id pub-id-type="pmc">5987907</article-id><article-id pub-id-type="doi">10.1177/2045894018769305</article-id><article-id pub-id-type="publisher-id">10.1177_2045894018769305</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Letter</subject></subj-group></article-categories><title-group><article-title>Riociguat treatment for portopulmonary hypertension: a subgroup analysis from the PATENT-1/-2 studies</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Cartin-Ceba</surname><given-names>Rodrigo</given-names></name><xref ref-type="aff" rid="aff1-2045894018769305">1</xref><xref ref-type="corresp" rid="corresp1-2045894018769305"/></contrib><contrib contrib-type="author"><name><surname>Halank</surname><given-names>Michael</given-names></name><xref ref-type="aff" rid="aff2-2045894018769305">2</xref></contrib><contrib contrib-type="author"><name><surname>Ghofrani</surname><given-names>Hossein-Ardeschir</given-names></name><xref ref-type="aff" rid="aff3-2045894018769305">3</xref><xref ref-type="aff" rid="aff4-2045894018769305">4</xref></contrib><contrib contrib-type="author"><name><surname>Humbert</surname><given-names>Marc</given-names></name><xref ref-type="aff" rid="aff5-2045894018769305">5</xref><xref ref-type="aff" rid="aff6-2045894018769305">6</xref><xref ref-type="aff" rid="aff7-2045894018769305">7</xref></contrib><contrib contrib-type="author"><name><surname>Mattson</surname><given-names>John</given-names></name><xref ref-type="aff" rid="aff8-2045894018769305">8</xref></contrib><contrib contrib-type="author"><name><surname>Fritsch</surname><given-names>Arno</given-names></name><xref ref-type="aff" rid="aff9-2045894018769305">9</xref></contrib><contrib contrib-type="author"><name><surname>Krowka</surname><given-names>Michael</given-names></name><xref ref-type="aff" rid="aff10-2045894018769305">10</xref></contrib></contrib-group><aff id="aff1-2045894018769305"><label>1</label>Division of Pulmonary Medicine, Department of Medicine, Mayo Clinic, Scottsdale, AZ, USA</aff><aff id="aff2-2045894018769305"><label>2</label>Department of Internal Medicine I, University Hospital Carl Gustav Carus, Technical University Dresden, Dresden, Germany</aff><aff id="aff3-2045894018769305"><label>3</label>University of Giessen and Marburg Lung Center (UGMLC), Giessen, Germany, member of the German Center of Lung Research (DZL)</aff><aff id="aff4-2045894018769305"><label>4</label>Department of Medicine, Imperial College London, London, UK</aff><aff id="aff5-2045894018769305"><label>5</label>Universit&#x000e9; Paris-Sud, member of Universit&#x000e9; Paris-Saclay, Le Kremlin-Bic&#x000ea;tre, France</aff><aff id="aff6-2045894018769305"><label>6</label>Assistance Publique &#x02013; H&#x000f4;pitaux de Paris, Service de Pneumologie, H&#x000f4;pital Bic&#x000ea;tre, Le Kremlin-Bic&#x000ea;tre, France</aff><aff id="aff7-2045894018769305"><label>7</label>Institut National de la Sant&#x000e9; et de la Recherche M&#x000e9;dicale UMR-S999, H&#x000f4;pital Marie Lannelongue, Le Plessis-Robinson, France</aff><aff id="aff8-2045894018769305"><label>8</label>Medical Affairs, Bayer US LLC, Whippany, NJ, USA</aff><aff id="aff9-2045894018769305"><label>9</label>Pharmaceutical Statistics, Bayer AG, Wuppertal, Germany</aff><aff id="aff10-2045894018769305"><label>10</label>Transplant Center, Mayo Clinic, Rochester, MN, USA</aff><author-notes><corresp id="corresp1-2045894018769305">Rodrigo Cartin-Ceba, MD, MSc, Associate Professor of Medicine, Consultant, Pulmonary and Critical Care Medicine, Mayo Clinic Arizona, 13400 East Shea Boulevard, Scottsdale, AZ 85259, USA. Email: <email>cartinceba.rodrigo@mayo.edu</email></corresp></author-notes><pub-date pub-type="epub"><day>22</day><month>3</month><year>2018</year></pub-date><pub-date pub-type="collection"><month>4</month><year>2018</year></pub-date><volume>8</volume><issue>2</issue><elocation-id>2045894018769305</elocation-id><history><date date-type="received"><day>22</day><month>2</month><year>2018</year></date><date date-type="accepted"><day>4</day><month>3</month><year>2018</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2018</copyright-statement><copyright-year>2018</copyright-year><copyright-holder content-type="society">SAGE Publications Ltd, or Pulmonary Vascular Research Institute, unless otherwise noted. Manuscript content on this site is licensed under Creative Commons Licenses</copyright-holder><license license-type="creative-commons" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/"><license-p>Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (<ext-link ext-link-type="uri" xlink:href="http://www.creativecommons.org/licenses/by-nc/4.0/">http://www.creativecommons.org/licenses/by-nc/4.0/</ext-link>) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (<ext-link ext-link-type="uri" xlink:href="https://us.sagepub.com/en-us/nam/open-access-at-sage">https://us.sagepub.com/en-us/nam/open-access-at-sage</ext-link>).</license-p></license></permissions><abstract><p>In patients with portopulmonary hypertension (n&#x02009;=&#x02009;13) included in the 12-week randomized placebo-controlled PATENT-1 trial, riociguat was well tolerated and improved 6-min walking distance (6MWD), World Health Organization functional class (WHO FC), and other efficacy parameters; 6MWD and WHO FC improvements were sustained over two years in the open-label extension, PATENT-2.</p></abstract><kwd-group><kwd>soluble guanylate cyclase stimulator</kwd><kwd>portal hypertension</kwd><kwd>pulmonary arterial hypertension</kwd></kwd-group><funding-group><award-group id="award1-2045894018769305"><funding-source id="funding1-2045894018769305"><institution-wrap><institution>Bayer AG</institution><institution-id institution-id-type="FundRef"/></institution-wrap></funding-source></award-group></funding-group><custom-meta-group><custom-meta><meta-name>cover-date</meta-name><meta-value>April-June 2018</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p>Portopulmonary hypertension (POPH) is a serious complication of portal hypertension from cirrhotic and non-cirrhotic causes. POPH is defined as the presence of pulmonary arterial hypertension (PAH) resulting from portal hypertension, and is classified in pulmonary hypertension (PH) group 1.<sup><xref rid="bibr1-2045894018769305" ref-type="bibr">1</xref></sup> In an analysis of the REVEAL registry, patients with POPH, including those with relatively better hemodynamics and functional classification at diagnosis, had significantly worse survival than patients with idiopathic or familial PAH.<sup><xref rid="bibr2-2045894018769305" ref-type="bibr">2</xref></sup> Other REVEAL data for risk levels in PAH subtypes based on predicted one-year survival classified POPH as high risk (70&#x02013;85% survival), with worse outcomes (&#x0003c;70% survival) only in scleroderma-related PH.<sup><xref rid="bibr3-2045894018769305" ref-type="bibr">3</xref></sup> Despite this poor prognosis, there is a lack of data from randomized controlled trials (RCTs) on the safety and efficacy of PAH-targeted therapies in POPH owing to the exclusion of such patients from most RCTs of PAH therapies to date.</p><p>Riociguat is the first-in-class soluble guanylate cyclase (sGC) stimulator<sup><xref rid="bibr4-2045894018769305" ref-type="bibr">4</xref></sup> and is approved in two separate PH indications: PAH and inoperable or persistent/recurrent chronic thromboembolic PH.<sup><xref rid="bibr4-2045894018769305" ref-type="bibr">4</xref>,<xref rid="bibr5-2045894018769305" ref-type="bibr">5</xref></sup> Riociguat acts indirectly and synergistically with endogenous nitric oxide and also directly stimulates sGC independently of nitric oxide.<sup><xref rid="bibr6-2045894018769305" ref-type="bibr">6</xref></sup> In PATENT-1, riociguat significantly improved exercise capacity and functional class (FC), and delayed clinical worsening, in patients with PAH.<sup><xref rid="bibr4-2045894018769305" ref-type="bibr">4</xref></sup> The improvements in exercise capacity and FC were sustained at two years in the long-term extension, PATENT-2.<sup><xref rid="bibr7-2045894018769305" ref-type="bibr">7</xref></sup></p><p>PATENT-1 was unique among PAH RCTs as it did not exclude patients with POPH. We performed an exploratory post-hoc analysis to evaluate riociguat treatment in patients with POPH who were included in the PATENT studies.</p><sec sec-type="methods" id="sec1-2045894018769305"><title>Methods</title><p>The full design and methodology for PATENT-1 and PATENT-2 have been published previously.<sup><xref rid="bibr4-2045894018769305" ref-type="bibr">4</xref>,<xref rid="bibr7-2045894018769305" ref-type="bibr">7</xref></sup> PATENT-1 was a 12-week, multicenter, double-blind, phase 3 study that investigated riociguat therapy in patients with symptomatic PAH.<sup><xref rid="bibr4-2045894018769305" ref-type="bibr">4</xref></sup> Patients were randomized to either placebo or riociguat individually dose-adjusted up to 2.5&#x02009;mg three times daily (t.i.d.), according to systolic blood pressure and signs and symptoms of hypotension. The primary endpoint was change from baseline to week 12 in 6-min walking distance (6MWD). Secondary endpoints included changes in World Health Organization (WHO) FC, <italic>N</italic>-terminal prohormone of brain natriuretic peptide (NT-proBNP) level, pulmonary vascular resistance (PVR), Borg dyspnea score, quality of life, and time to clinical worsening (first occurrence of: all-cause death; heart/lung transplantation; atrial septostomy; hospitalization due to persistent worsening of PAH; start of new PAH treatment or modification of pre-existing prostanoid treatment; persistent decrease of 6MWD &#x0003e;15% from baseline or&#x02009;&#x0003e;&#x02009;30% versus the last study-related measurement due to worsening PAH; or persistent worsening of WHO FC due to PAH deterioration). Exploratory hemodynamic endpoints included cardiac index, mean pulmonary artery pressure (mPAP), and right atrial pressure. Patients completing PATENT-1 without ongoing riociguat-related serious adverse events (SAEs) were eligible for the open-label, long-term extension, PATENT-2, in which all patients received riociguat up to 2.5&#x02009;mg t.i.d.</p><p>The studies were conducted in accordance with Good Clinical Practice Guidelines and the Declaration of Helsinki. Institutional review board approval of the protocol was obtained at each participating center before enrollment. All patients provided written informed consent.</p><p>An exploratory, post-hoc analysis was conducted for the subgroup of patients with POPH. Endpoints were analyzed descriptively using observed data and were presented as individual patient data or analyzed as change from baseline to the last observed value (not including follow-up) among patients who completed the study or withdrew. Continuous data are presented as medians; categorical data are presented as counts and percentages.</p></sec><sec sec-type="results" id="sec2-2045894018769305"><title>Results</title><sec id="sec3-2045894018769305"><title>Study population</title><p>Of 443 patients enrolled in PATENT-1, 13 had POPH; of these, 11 were randomized to receive riociguat 2.5&#x02009;mg&#x02013;maximum t.i.d. and two received placebo. The mean&#x02009;&#x000b1;&#x02009;standard deviation age of the POPH subgroup was 57&#x02009;&#x000b1;&#x02009;9 years (median 60 years), and the majority were women (n&#x02009;=&#x02009;10, 77%) and in WHO FC III (n&#x02009;=&#x02009;8, 62%) (Table S1).</p></sec><sec id="sec4-2045894018769305"><title>Efficacy</title><p>In the POPH subgroup, at PATENT-1 week 12, median 6MWD increased from baseline by&#x02009;+&#x02009;48&#x02009;m in riociguat-treated patients and&#x02009;+&#x02009;3&#x02009;m in placebo patients (Table S2). Changes from baseline in 6MWD in the POPH subgroup were maintained over two years in PATENT-2 (Fig. S1) and appeared comparable to those previously reported in the overall PATENT-2 population.<sup><xref rid="bibr7-2045894018769305" ref-type="bibr">7</xref></sup> At PATENT-1 week 12, WHO FC improved, stabilized, or worsened in four, six, and zero riociguat-treated patients and one, one, and zero placebo patients, respectively (Table S2). Improvements in WHO FC were maintained at two years in PATENT-2 (Fig. S2). Median NT-proBNP levels and median PVR decreased from baseline at week 12 with riociguat and increased with placebo (Table S2). <xref ref-type="fig" rid="fig1-2045894018769305">Fig. 1</xref> shows individual patient data for change in 6MWD, NT-proBNP, PVR, cardiac index, and mPAP over 12 weeks in PATENT-1.
<fig id="fig1-2045894018769305" orientation="portrait" position="float"><label>Fig. 1.</label><caption><p>Individual patient data for (a) 6MWD, (b) NT-proBNP level, (c) PVR, (d) cardiac index, and (e) mPAP over time in patients with POPH in PATENT-1. 6MWD, 6-min walking distance; mPAP, mean pulmonary arterial pressure; NT-proBNP, <italic>N-</italic>terminal prohormone of brain natriuretic peptide; POPH, portopulmonary hypertension; PVR, pulmonary vascular resistance.</p></caption><graphic xlink:href="10.1177_2045894018769305-fig1"/></fig></p><p>In PATENT-1, one (riociguat-treated) patient with POPH experienced a clinical worsening event (death due to sepsis; not considered study drug-related). In PATENT-2, when most patients had received riociguat for&#x02009;&#x02265;&#x02009;2 years, there were four clinical worsening events in two patients (17%) with POPH: one hospitalization due to worsening PH; one start of new PH treatment; and two deaths.</p></sec><sec id="sec5-2045894018769305"><title>Safety</title><p>In the POPH subgroup of PATENT-1, the most frequent adverse events (AEs) with riociguat were peripheral edema and headache, which occurred with comparable incidence to the overall PATENT-1 population (Table S3).<sup><xref rid="bibr4-2045894018769305" ref-type="bibr">4</xref></sup> One riociguat-treated patient experienced an SAE of acute renal failure (considered study drug-related), and later experienced SAEs of bronchopneumonia and sepsis, resulting in death (not considered study drug-related).</p><p>In the POPH subgroup of PATENT-2 (n&#x02009;=&#x02009;12), the most common AEs were nasopharyngitis (n&#x02009;=&#x02009;5), peripheral edema (n&#x02009;=&#x02009;4), anemia (n&#x02009;=&#x02009;4), and cough (n&#x02009;=&#x02009;4). Nine patients experienced an SAE in PATENT-2; in one patient the SAE (acute renal failure) was considered study drug-related. One patient had a particularly high NT-proBNP level (<xref ref-type="fig" rid="fig1-2045894018769305">Fig. 1</xref>), was hospitalized due to PAH during PATENT-2, and subsequently died.</p></sec></sec><sec sec-type="discussion" id="sec6-2045894018769305"><title>Discussion</title><p>In this post-hoc, exploratory analysis of the PATENT-1/-2 studies,<sup><xref rid="bibr4-2045894018769305" ref-type="bibr">4</xref>,<xref rid="bibr7-2045894018769305" ref-type="bibr">7</xref></sup> riociguat-treated patients with POPH showed improvements in 6MWD, WHO FC, PVR, and several other secondary efficacy parameters over 12 weeks. The improvements in 6MWD and WHO FC were maintained over two years in PATENT-2.<sup><xref rid="bibr7-2045894018769305" ref-type="bibr">7</xref></sup> Riociguat was well tolerated by patients with POPH, with a comparable safety profile to other PAH subgroups in PATENT-1<sup><xref rid="bibr8-2045894018769305" ref-type="bibr">8</xref><xref rid="bibr9-2045894018769305" ref-type="bibr"/>&#x02013;<xref rid="bibr10-2045894018769305" ref-type="bibr">10</xref></sup> and PATENT-2.<sup><xref rid="bibr7-2045894018769305" ref-type="bibr">7</xref></sup></p><p>Although POPH treatment typically follows the same algorithm as for other PAH subtypes, patients with POPH have been excluded from most RCTs of PAH therapies to date. Uncontrolled, small series and case reports have suggested that PAH-targeted therapies could benefit patients with POPH,<sup><xref rid="bibr11-2045894018769305" ref-type="bibr">11</xref><xref rid="bibr12-2045894018769305" ref-type="bibr"/><xref rid="bibr13-2045894018769305" ref-type="bibr"/>&#x02013;<xref rid="bibr14-2045894018769305" ref-type="bibr">14</xref></sup> e.g. as a preoperative &#x0201c;bridge&#x0201d; to liver transplantation. By improving hemodynamic and clinical parameters, PAH therapy can induce a response that meets liver transplantation eligibility criteria;<sup><xref rid="bibr15-2045894018769305" ref-type="bibr">15</xref></sup> however, careful patient selection is required and this approach is not currently generally established. Specific guidelines for managing POPH have been recently published;<sup><xref rid="bibr16-2045894018769305" ref-type="bibr">16</xref></sup> however, there have been no peer-reviewed, published data until now on the role of new medications, such as riociguat, in POPH treatment, nor any published case reports describing the outcomes of sGC stimulators in POPH.<sup><xref rid="bibr11-2045894018769305" ref-type="bibr">11</xref>,<xref rid="bibr15-2045894018769305" ref-type="bibr">15</xref></sup> Our post-hoc analysis is thus of importance as PATENT-1 is the first RCT in PAH that included patients with POPH (3% of the PATENT-1 overall population).<sup><xref rid="bibr4-2045894018769305" ref-type="bibr">4</xref>,<xref rid="bibr17-2045894018769305" ref-type="bibr">17</xref></sup></p><p>Riociguat is approved in patients with group 1 PAH to improve exercise capacity and FC, and to delay clinical worsening.<sup><xref rid="bibr17-2045894018769305" ref-type="bibr">17</xref></sup> POPH is one cause of group 1 PAH. Riociguat may have potential advantages in patients with POPH because of its generally favorable liver safety profile and the possibility to combine it with a prostanoid. Routine liver function monitoring is not required during treatment. However, as higher riociguat exposure has been observed in patients with moderate hepatic impairment (Child&#x02013;Pugh Class B),<sup><xref rid="bibr18-2045894018769305" ref-type="bibr">18</xref></sup> particular care is required during individual dose adjustment in these patients. Riociguat is not recommended in patients with severe hepatic impairment (Child&#x02013;Pugh Class C) due to a lack of data in these patients. The risk of hypotension is another concern in the POPH population, and riociguat should be used cautiously in these patients. Preclinical data also suggest a potential additional benefit of riociguat on liver characteristics; riociguat significantly decreased portal pressure and liver fibrosis in cirrhotic rat models, although this effect has yet to be demonstrated in humans.<sup><xref rid="bibr19-2045894018769305" ref-type="bibr">19</xref></sup></p><p>Our study has several limitations. First, this is a post-hoc analysis of a large RCT. Second, the low number of patients (and predominance of women) in this analysis precludes firm conclusions. Third, PATENT-1 excluded patients receiving intravenous prostanoids and the effect of riociguat in such patients is unknown. Patients receiving phosphodiesterase type 5 inhibitors were also excluded; riociguat is contraindicated in combination with these agents owing to high rates of hypotension and treatment discontinuation in such patients.<sup><xref rid="bibr20-2045894018769305" ref-type="bibr">20</xref></sup> Finally, details of liver-related clinical characteristics and outcomes associated with the small POPH population are lacking.</p><p>In conclusion, in this post-hoc analysis of the first RCT in PAH to include patients with POPH, riociguat treatment appeared to be associated with improvements in important primary and secondary efficacy parameters over 12 weeks in patients with POPH. Riociguat was generally well tolerated, with a similar safety profile to that seen in the overall PATENT-1 population and the long-term PATENT-2 study. Given the small sample size, larger prospective studies are warranted to investigate riociguat for the treatment of POPH.</p></sec><sec sec-type="supplementary-material" specific-use="figshare"><title>Supplemental Material</title><supplementary-material content-type="local-data" id="suppl1-2045894018769305"><caption><title>Supplemental material for Riociguat treatment for portopulmonary hypertension: a subgroup analysis from the PATENT-1/-2 studies</title></caption><media xlink:href="Supplemental_material.pdf"><caption><p>Click here for additional data file.</p></caption></media><p>Supplemental material for Riociguat treatment for portopulmonary hypertension: a subgroup analysis from the PATENT-1/-2 studies by Rodrigo Cartin-Ceba, Michael Halank, Hossein-Ardeschir Ghofrani, Marc Humbert, John Mattson, Arno Fritsch and Michael Krowka in Pulmonary Circulation</p></supplementary-material></sec></body><back><ack><title>Acknowledgements</title><p>Medical writing assistance was provided by Adelphi Communications Ltd (Bollington, UK), funded by Bayer AG (Berlin, Germany).</p></ack><sec id="sec7-2045894018769305"><title>Conflict of interest</title><p>RC-C has nothing to disclose. MHa reports personal fees (lectures) from Actelion, Bayer AG, GlaxoSmithKline, Merck Sharp &#x00026; Dohme, and Optimal Medical Therapies (OMT); non-financial support (travel) from Actelion and OMT; and other (advisory board) from Actelion, Bayer AG, and GlaxoSmithKline (GSK), outside the submitted work. H-AG reports grants from DFG (German Research Foundation); honoraria from Actelion, Bayer, Ergonex, Gilead, GSK, Novartis, and Pfizer; consultancy fees from AbbVie, Actelion, Bayer, Bellerophon Pulse Technologies, Ergonex, Gilead, GSK, Medscape, Merck Sharp &#x00026; Dohme, Novartis, OMT, Pfizer, and Web MD Global; and speaker&#x02019;s bureau fees from Actelion, Bayer, Ergonex, Gilead, GSK, Novartis, and Pfizer. MHu reports personal fees from Actelion, Arena, Bayer, GSK, Merck, Novartis, Pfizer, and United Therapeutics. JM and AF are full-time employees of Bayer AG. MK reports involvement in the steering committee for the PORTICO trial, supported by Actelion, during the conduct of the study.</p></sec><sec id="sec8-2045894018769305"><title>Funding</title><p>This study was supported by Bayer AG (Berlin, Germany).</p></sec><ref-list><title>References</title><ref id="bibr1-2045894018769305"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gali&#x000e8;</surname><given-names>N</given-names></name><name><surname>Humbert</surname><given-names>M</given-names></name><name><surname>Vachiery</surname><given-names>JL</given-names></name><etal>et al.</etal></person-group>
<article-title>2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The joint task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT)</article-title>. <source>Eur Respir J</source>
<year>2015</year>; <volume>46</volume>: <fpage>903</fpage>&#x02013;<lpage>975</lpage>.<pub-id pub-id-type="pmid">26318161</pub-id></mixed-citation></ref><ref id="bibr2-2045894018769305"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krowka</surname><given-names>MJ</given-names></name><name><surname>Miller</surname><given-names>DP</given-names></name><name><surname>Barst</surname><given-names>RJ</given-names></name><etal>et al.</etal></person-group>
<article-title>Portopulmonary hypertension: a report from the US-based REVEAL Registry</article-title>. <source>Chest</source>
<year>2012</year>; <volume>141</volume>: <fpage>906</fpage>&#x02013;<lpage>915</lpage>.<pub-id pub-id-type="pmid">21778257</pub-id></mixed-citation></ref><ref id="bibr3-2045894018769305"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benza</surname><given-names>RL</given-names></name><name><surname>Miller</surname><given-names>DP</given-names></name><name><surname>Gomberg-Maitland</surname><given-names>M</given-names></name><etal>et al.</etal></person-group>
<article-title>Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL)</article-title>. <source>Circulation</source>
<year>2010</year>; <volume>122</volume>: <fpage>164</fpage>&#x02013;<lpage>172</lpage>.<pub-id pub-id-type="pmid">20585012</pub-id></mixed-citation></ref><ref id="bibr4-2045894018769305"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghofrani</surname><given-names>HA</given-names></name><name><surname>Galie</surname><given-names>N</given-names></name><name><surname>Grimminger</surname><given-names>F</given-names></name><etal>et al.</etal></person-group>
<article-title>Riociguat for the treatment of pulmonary arterial hypertension</article-title>. <source>N Engl J Med</source>
<year>2013</year>; <volume>369</volume>: <fpage>330</fpage>&#x02013;<lpage>340</lpage>.<pub-id pub-id-type="pmid">23883378</pub-id></mixed-citation></ref><ref id="bibr5-2045894018769305"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghofrani</surname><given-names>HA</given-names></name><name><surname>D'Armini</surname><given-names>AM</given-names></name><name><surname>Grimminger</surname><given-names>F</given-names></name><etal>et al.</etal></person-group>
<article-title>Riociguat for the treatment of chronic thromboembolic pulmonary hypertension</article-title>. <source>N Engl J Med</source>
<year>2013</year>; <volume>369</volume>: <fpage>319</fpage>&#x02013;<lpage>329</lpage>.<pub-id pub-id-type="pmid">23883377</pub-id></mixed-citation></ref><ref id="bibr6-2045894018769305"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stasch</surname><given-names>JP</given-names></name><name><surname>Evgenov</surname><given-names>OV</given-names></name></person-group>
<article-title>Soluble guanylate cyclase stimulators in pulmonary hypertension</article-title>. <source>Handb Exp Pharmacol</source>
<year>2013</year>; <volume>218</volume>: <fpage>279</fpage>&#x02013;<lpage>313</lpage>.<pub-id pub-id-type="pmid">24092345</pub-id></mixed-citation></ref><ref id="bibr7-2045894018769305"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghofrani</surname><given-names>HA</given-names></name><name><surname>Grimminger</surname><given-names>F</given-names></name><name><surname>Grunig</surname><given-names>E</given-names></name><etal>et al.</etal></person-group>
<article-title>Predictors of long-term outcomes in patients treated with riociguat for pulmonary arterial hypertension: data from the PATENT-2 open-label, randomised, long-term extension trial</article-title>. <source>Lancet Respir Med</source>
<year>2016</year>; <volume>4</volume>: <fpage>361</fpage>&#x02013;<lpage>371</lpage>.<pub-id pub-id-type="pmid">27067479</pub-id></mixed-citation></ref><ref id="bibr8-2045894018769305"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gali&#x000e8;</surname><given-names>N</given-names></name><name><surname>Grimminger</surname><given-names>F</given-names></name><name><surname>Grunig</surname><given-names>E</given-names></name><etal>et al.</etal></person-group>
<article-title>Comparison of hemodynamic parameters in treatment-na&#x000ef;ve and pre-treated patients with pulmonary arterial hypertension in the randomized phase III PATENT-1 study</article-title>. <source>J Heart Lung Transplant</source>
<year>2017</year>; <volume>36</volume>: <fpage>509</fpage>&#x02013;<lpage>519</lpage>.<pub-id pub-id-type="pmid">28190787</pub-id></mixed-citation></ref><ref id="bibr9-2045894018769305"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Humbert</surname><given-names>M</given-names></name><name><surname>Coghlan</surname><given-names>JG</given-names></name><name><surname>Ghofrani</surname><given-names>HA</given-names></name><etal>et al.</etal></person-group>
<article-title>Riociguat for the treatment of pulmonary arterial hypertension associated with connective tissue disease: results from PATENT-1 and PATENT-2</article-title>. <source>Ann Rheum Dis</source>
<year>2017</year>; <volume>76</volume>: <fpage>422</fpage>&#x02013;<lpage>426</lpage>.<pub-id pub-id-type="pmid">27457511</pub-id></mixed-citation></ref><ref id="bibr10-2045894018769305"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosenkranz</surname><given-names>S</given-names></name><name><surname>Ghofrani</surname><given-names>HA</given-names></name><name><surname>Beghetti</surname><given-names>M</given-names></name><etal>et al.</etal></person-group>
<article-title>Riociguat for pulmonary arterial hypertension associated with congenital heart disease</article-title>. <source>Heart</source>
<year>2015</year>; <volume>101</volume>: <fpage>1792</fpage>&#x02013;<lpage>1799</lpage>.<pub-id pub-id-type="pmid">26135803</pub-id></mixed-citation></ref><ref id="bibr11-2045894018769305"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DuBrock</surname><given-names>HM</given-names></name><name><surname>Channick</surname><given-names>RN</given-names></name><name><surname>Krowka</surname><given-names>MJ</given-names></name></person-group>
<article-title>What's new in the treatment of portopulmonary hypertension?</article-title>
<source>Expert Rev Gastroenterol Hepatol</source>
<year>2015</year>; <volume>9</volume>: <fpage>983</fpage>&#x02013;<lpage>992</lpage>.<pub-id pub-id-type="pmid">25882070</pub-id></mixed-citation></ref><ref id="bibr12-2045894018769305"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eriksson</surname><given-names>C</given-names></name><name><surname>Gustavsson</surname><given-names>A</given-names></name><name><surname>Kronvall</surname><given-names>T</given-names></name><etal>et al.</etal></person-group>
<article-title>Hepatotoxicity by bosentan in a patient with portopulmonary hypertension: a case-report and review of the literature</article-title>. <source>J Gastrointestin Liver Dis</source>
<year>2011</year>; <volume>20</volume>: <fpage>77</fpage>&#x02013;<lpage>80</lpage>.<pub-id pub-id-type="pmid">21451802</pub-id></mixed-citation></ref><ref id="bibr13-2045894018769305"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Halank</surname><given-names>M</given-names></name><name><surname>Knudsen</surname><given-names>L</given-names></name><name><surname>Seyfarth</surname><given-names>HJ</given-names></name><etal>et al.</etal></person-group>
<article-title>Ambrisentan improves exercise capacity and symptoms in patients with portopulmonary hypertension</article-title>. <source>Z Gastroenterol</source>
<year>2011</year>; <volume>49</volume>: <fpage>1258</fpage>&#x02013;<lpage>1262</lpage>.<pub-id pub-id-type="pmid">21887662</pub-id></mixed-citation></ref><ref id="bibr14-2045894018769305"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kahler</surname><given-names>CM</given-names></name><name><surname>Graziadei</surname><given-names>I</given-names></name><name><surname>Vogelsinger</surname><given-names>H</given-names></name><etal>et al.</etal></person-group>
<article-title>Successful treatment of portopulmonary hypertension with the selective endothelin receptor antagonist Sitaxentan</article-title>. <source>Wien Klin Wochenschr</source>
<year>2011</year>; <volume>123</volume>: <fpage>248</fpage>&#x02013;<lpage>252</lpage>.<pub-id pub-id-type="pmid">21451953</pub-id></mixed-citation></ref><ref id="bibr15-2045894018769305"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Toapanta-Yanchapaxi</surname><given-names>L</given-names></name></person-group>
<article-title>Portopulmonar hypertension: Is there something new?</article-title>
<source>J Rare Dis Res Treat</source>
<year>2017</year>; <volume>2</volume>: <fpage>46</fpage>&#x02013;<lpage>56</lpage>.</mixed-citation></ref><ref id="bibr16-2045894018769305"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krowka</surname><given-names>MJ</given-names></name><name><surname>Fallon</surname><given-names>MB</given-names></name><name><surname>Kawut</surname><given-names>SM</given-names></name><etal>et al.</etal></person-group>
<article-title>International Liver Transplant Society Practice Guidelines: diagnosis and management of hepatopulmonary syndrome and portopulmonary hypertension</article-title>. <source>Transplantation</source>
<year>2016</year>; <volume>100</volume>: <fpage>1440</fpage>&#x02013;<lpage>1452</lpage>.<pub-id pub-id-type="pmid">27326810</pub-id></mixed-citation></ref><ref id="bibr17-2045894018769305"><label>17</label><mixed-citation publication-type="other"><comment>Bayer A.G. Adempas, US prescribing information. Available at: <ext-link ext-link-type="uri" xlink:href="http://labeling.bayerhealthcare.com/html/products/pi/Adempas_PI.pdf2017">http://labeling.bayerhealthcare.com/html/products/pi/Adempas_PI.pdf2017</ext-link></comment>.</mixed-citation></ref><ref id="bibr18-2045894018769305"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frey</surname><given-names>R</given-names></name><name><surname>Becker</surname><given-names>C</given-names></name><name><surname>Unger</surname><given-names>S</given-names></name><etal>et al.</etal></person-group>
<article-title>Assessment of the effects of hepatic impairment and smoking on the pharmacokinetics of a single oral dose of the soluble guanylate cyclase stimulator riociguat (BAY 63-2521)</article-title>. <source>Pulm Circ</source>
<year>2016</year>; <volume>6</volume>: <fpage>S5</fpage>&#x02013;<lpage>S14</lpage>.<pub-id pub-id-type="pmid">27162628</pub-id></mixed-citation></ref><ref id="bibr19-2045894018769305"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schwabl</surname><given-names>P</given-names></name><name><surname>Brusilowska</surname><given-names>K</given-names></name><name><surname>Riedl</surname><given-names>F</given-names></name><etal>et al.</etal></person-group>
<article-title>The guanylyl cyclase stlmulator rloclguat reduces liver fibrosis and portal pressure in cirrhotic rats</article-title>. <source>J Hepatol</source>
<year>2016</year>; <volume>64</volume>: <fpage>S140</fpage>.</mixed-citation></ref><ref id="bibr20-2045894018769305"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gali&#x000e8;</surname><given-names>N</given-names></name><name><surname>Muller</surname><given-names>K</given-names></name><name><surname>Scalise</surname><given-names>AV</given-names></name><etal>et al.</etal></person-group>
<article-title>PATENT PLUS: a blinded, randomised and extension study of riociguat plus sildenafil in PAH</article-title>. <source>Eur Respir J</source>
<year>2015</year>; <volume>45</volume>: <fpage>1314</fpage>&#x02013;<lpage>1322</lpage>.<pub-id pub-id-type="pmid">25657022</pub-id></mixed-citation></ref></ref-list></back></article>